Valfin A Tablet combines Amlodipine 5 mg, a calcium channel blocker, with Valsartan 80 mg, an angiotensin II receptor blocker (ARB), to provide effective blood pressure control in hypertensive patients. This combination addresses multiple mechanisms of hypertension, improving vascular relaxation and reducing cardiac workload.
Belonging to the cardiology and anti-hypertensive segment, this tablet is prescribed for patients who require enhanced blood pressure control or need combination therapy for optimal cardiovascular protection.
The dual-action formulation ensures better efficacy, improved patient adherence, and reduced risk of cardiovascular complications compared to monotherapy. It is particularly suitable for patients with coexisting cardiac risks or resistant hypertension.
For PCD pharma franchise partners, distributors, exporters, and third-party manufacturers, Valfin A Tablet represents a profitable B2B opportunity, catering to hospitals, clinics, and retail pharmacies across India, with strong and consistent demand in the cardiovascular therapy segment.